147 related articles for article (PubMed ID: 36496490)
1. Predicting Lymph Node Metastases in Patients with Biopsy-Proven Ductal Carcinoma In Situ of the Breast: Development and Validation of the DCIS-met Model.
Meurs CJC; van Rosmalen J; Menke-Pluijmers MBE; Siesling S; Westenend PJ
Ann Surg Oncol; 2023 Apr; 30(4):2142-2151. PubMed ID: 36496490
[TBL] [Abstract][Full Text] [Related]
2. A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged From Ductal Carcinoma in Situ.
Yoo TK; Kim SJ; Lee J; Lee SB; Lee SJ; Park HY; Park HK; Chae BJ; Eom YH; Kim HS; Song BJ
Clin Breast Cancer; 2020 Jun; 20(3):e281-e289. PubMed ID: 32147404
[TBL] [Abstract][Full Text] [Related]
3. Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS.
Nicholson S; Hanby A; Clements K; Kearins O; Lawrence G; Dodwell D; Bishop H; Thompson A;
Eur J Surg Oncol; 2015 Jan; 41(1):86-93. PubMed ID: 25441934
[TBL] [Abstract][Full Text] [Related]
4. Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.
Shin YD; Lee HM; Choi YJ
BMC Surg; 2021 Mar; 21(1):159. PubMed ID: 33752671
[TBL] [Abstract][Full Text] [Related]
5. Is Sentinel Lymph Node Biopsy Necessary for Ductal Carcinoma In Situ Patients Undergoing Mastectomy?
Miller-Ocuin JL; Howard-McNatt M; Levine EA; Chiba A
Am Surg; 2020 Aug; 86(8):955-957. PubMed ID: 32862671
[TBL] [Abstract][Full Text] [Related]
6. Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified?
Sorrentino L; Sartani A; Bossi D; Amadori R; Nebuloni M; Truffi M; Bonzini M; Riggio E; Foschi D; Corsi F
Breast J; 2018 May; 24(3):325-333. PubMed ID: 29024241
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy.
Kotani H; Yoshimura A; Adachi Y; Ishiguro J; Hisada T; Ichikawa M; Gondou N; Hattori M; Kondou N; Sawaki M; Fujita T; Iwata H
Breast Cancer; 2016 Mar; 23(2):190-4. PubMed ID: 24989112
[TBL] [Abstract][Full Text] [Related]
8. Predictors of invasion and axillary lymph node metastasis in patients with a core biopsy diagnosis of ductal carcinoma in situ: an analysis of 255 cases.
Han JS; Molberg KH; Sarode V
Breast J; 2011; 17(3):223-9. PubMed ID: 21545433
[TBL] [Abstract][Full Text] [Related]
9. Is Axillary Assessment of Ductal Carcinoma In Situ of the Breast Necessary in All Cases?
Bellver G; Buch E; Ripoll F; Adrianzen M; Bermejo B; Burgues O; Julve A; Ortega J
J Surg Res; 2022 Mar; 271():145-153. PubMed ID: 34902737
[TBL] [Abstract][Full Text] [Related]
10. Sentinel Node Procedure Obsolete in Lumpectomy for Ductal Carcinoma In Situ.
Heymans C; van Bastelaar J; Visschers RGJ; Vissers YLJ
Clin Breast Cancer; 2017 Jun; 17(3):e87-e93. PubMed ID: 28162949
[TBL] [Abstract][Full Text] [Related]
11. Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
Ramzi S; Najeeb E; Coulthard J; Jenkins S
Breast Cancer Res Treat; 2020 Jul; 182(1):47-54. PubMed ID: 32430678
[TBL] [Abstract][Full Text] [Related]
12. Diffusion-weighted Breast MRI in Prediction of Upstaging in Women with Biopsy-proven Ductal Carcinoma in Situ.
Lee SA; Lee Y; Ryu HS; Jang MJ; Moon WK; Moon HG; Lee SH
Radiology; 2022 Nov; 305(2):307-316. PubMed ID: 35787199
[TBL] [Abstract][Full Text] [Related]
13. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
Sakr R; Barranger E; Antoine M; Prugnolle H; Daraï E; Uzan S
J Surg Oncol; 2006 Oct; 94(5):426-30. PubMed ID: 16967457
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision.
Kim J; Han W; Lee JW; You JM; Shin HC; Ahn SK; Moon HG; Cho N; Moon WK; Park IA; Noh DY
Breast; 2012 Oct; 21(5):641-5. PubMed ID: 22749854
[TBL] [Abstract][Full Text] [Related]
15. Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
Huang CY; Chang RF; Lin CY; Hsieh MS; Liao PC; Wang YJ; Kao YC; Porta L; Lin PY; Lee CC; Lee YH
Histopathology; 2024 May; 84(6):983-1002. PubMed ID: 38288642
[TBL] [Abstract][Full Text] [Related]
16. Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy.
Mittendorf EA; Arciero CA; Gutchell V; Hooke J; Shriver CD
Curr Surg; 2005; 62(2):253-7. PubMed ID: 15796952
[TBL] [Abstract][Full Text] [Related]
17. Selective approach to radionuclide-guided sentinel lymph node biopsy in high-risk ductal carcinoma in situ of the breast.
Usmani S; Khan HA; Al Saleh N; abu Huda F; Marafi F; Amanguno HG; Al Nafisi N; Al Kandari F
Nucl Med Commun; 2011 Nov; 32(11):1084-7. PubMed ID: 21862942
[TBL] [Abstract][Full Text] [Related]
18. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy.
Meijnen P; Oldenburg HS; Loo CE; Nieweg OE; Peterse JL; Rutgers EJ
Br J Surg; 2007 Aug; 94(8):952-6. PubMed ID: 17440955
[TBL] [Abstract][Full Text] [Related]
19. Revisit the practice of lymph node biopsy in patients diagnosed as ductal carcinoma in situ before operation: a retrospective analysis of 682 cases and evaluation of the role of breast MRI.
Lai HW; Chang YL; Chen ST; Chang YJ; Wu WP; Chen DR; Kuo SJ; Liao CY; Wu HK
World J Surg Oncol; 2021 Sep; 19(1):263. PubMed ID: 34470633
[TBL] [Abstract][Full Text] [Related]
20. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit.
Moore KH; Sweeney KJ; Wilson ME; Goldberg JI; Buchanan CL; Tan LK; Liberman L; Turner RR; Lagios MD; Cody Iii HS; Giuliano AE; Silverstein MJ; Van Zee KJ
Ann Surg Oncol; 2007 Oct; 14(10):2911-7. PubMed ID: 17597346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
